Holen Sie sich die Stockscreener-App
6.13
0.33%
0.02
Handel nachbörslich:
6.04
-0.09
-1.47%
Schlusskurs vom Vortag:
$6.11
Offen:
$6.38
24-Stunden-Volumen:
260.81K
Relative Volume:
4.50
Marktkapitalisierung:
$168.73M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-9.19%
1M Leistung:
-48.49%
6M Leistung:
-22.99%
1J Leistung:
+0.00%
1-Tages-Spanne:
$5.80
$6.39
1-Wochen-Bereich:
$5.50
$6.7499
52-Wochen-Spanne:
$5.50
$11.99
Actuate Therapeutics Inc Stock (ACTU) Company Profile
Firmenname
Actuate Therapeutics Inc
Sektor
Branche
Telefon
847-986-4190
Adresse
1751 RIVER RUN, FORT WORTH
Vergleichen Sie ACTU mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACTU
Actuate Therapeutics Inc
|
6.13 | 168.73M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Actuate Therapeutics Inc Stock (ACTU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Eingeleitet | Craig Hallum | Buy |
| 2025-03-17 | Eingeleitet | H.C. Wainwright | Buy |
Actuate Therapeutics Inc Aktie (ACTU) Neueste Nachrichten
Key Trends Shaping the Future of Locally Advanced Pancreatic Cancer Market: Innovative Approaches In Treati... - WhaTech
Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - GlobeNewswire
Elraglusib significantly lowers risk of death in PDAC patients: Trial - Rare Cancer News
Actuate Therapeutics Hosts Key Opinion Leader Event - TipRanks
Actuate Therapeutics (NASDAQ:ACTU) Price Target Raised to $20.00 at HC Wainwright - Defense World
Actuate Therapeutics shares highlights from KOL eventon elraglusib data - Yahoo Finance
Promising Clinical Trial Results Justify Buy Rating for Actuate Therapeutics’ Elraglusib - TipRanks
2 Biopharmaceutical Stocks Focused on Cancer That Wall Street Predicts Will More Than Double - inkl
Actuate Therapeutics Shares Highlights from KOL Event on - GlobeNewswire
Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer - Yahoo Finance
Actuate Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Acral Lentiginous Melanoma Pipeline Appears Robust With 5+ Key Pharma Companies Actively Working In The Therapeutics Segment Delveinsight - MENAFN.com
Actuate Therapeutics, Inc. (ACTU)’s Elraglusib Elraglusib Trial Hits Key Goals in Pancreatic Cancer - Insider Monkey
Actuate Therapeutics: Elraglusib trial meets key endpoint in pancreatic cancer (ACTU:NASDAQ) - Seeking Alpha
Actuate Therapeutics Reports Positive Phase 2 Trial Results for Elraglusib in Metastatic Pancreatic Cancer, Improving Overall Survival - Nasdaq
Actuate Therapeutics Presents Topline Elraglusib Phase 2 - GlobeNewswire
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer - GlobeNewswire Inc.
P2P Group And NATO Registered Partner Aliter Showcases Inturai Stealthwave Video - The Globe and Mail
Actuate Therapeutics Elects Directors at Annual Meeting - TipRanks
Actuate Therapeutics Reports Phase 2 Trial Success Showing Improved Survival in Metastatic Pancreatic Cancer - Nasdaq
Actuate Therapeutics Announces Details for 2025 ASCO Annual - GlobeNewswire
BIOS Capital Management LP Takes $78.75 Million Position in Actuate Therapeutics (NASDAQ:ACTU) - Defense World
Mercer Global Advisors Inc. ADV Acquires New Shares in Actuate Therapeutics (NASDAQ:ACTU) - Defense World
Apple Is Threatening to Challenge Alphabet's Empire: Is the Stock a Buy? - The Globe and Mail
Adding elraglusib seen to improve survival in pancreatic cancer trial - Rare Cancer News
Analysts Are Bullish on Top Healthcare Stocks: Lineage Therap (LCTX), Tenon Medical, Inc. (TNON) - The Globe and Mail
BlossomHill Therapeutics Appoints Jason Keyes as Chief Financial Officer and Executive Vice President - The Manila Times
Envestnet Asset Management Inc. Invests $83,000 in Actuate Therapeutics (NASDAQ:ACTU) - Defense World
Managing Adverse Events in Pembrolizumab Therapy for Gastric Cancer - Targeted Oncology
Elraglusib Combo Demonstrates OS Benefit in Metastatic Pancreatic Cancer - CancerNetwork
Actuate jumps as lead drug succeeds in mid-stage trial for pancreatic cancer - MSN
Theriva’s VCN-01 improves survival in phase IIb pancreatic cancer trial - BioWorld MedTech
Actuate Therapeutics to Host KOL Event on Topline Phase 2 - GlobeNewswire
Actuate Therapeutics to host KOL event on Phase 2 elraglusib data - TipRanks
Actuate Therapeutics to Host KOL Event on Topline Phase 2 Data of Elraglusib in Metastatic Pancreatic Ductal Adenocarcinoma During ASCO Annual Meeting - Yahoo Finance
PTC hits Huntington biomarker, but approval path still uncertain - biocentury.com
Lilly to pay up to $415M in ALS deal; Actuate’s mid-stage pancreatic cancer data - Endpoints News
Actuate Therapeutics Reports Positive Data From Phase 2 Study Of Elraglusib In Pancreatic Cancer - Nasdaq
Actuate Therapeutics Announces Positive Phase 2 Trial Results - TipRanks
Actuate stock jumps after cancer trial data (ACTU:NASDAQ) - Seeking Alpha
Elraglusib shows survival benefit in pancreatic cancer trial - Investing.com Australia
Actuate Therapeutics Announces Statistically Significant Topline Results from Global Phase 2 Trial of Elraglusib in First-Line Treatment of Metastatic Pancreatic Cancer - GlobeNewswire
Elraglusib shows survival benefit in pancreatic cancer trial By Investing.com - Investing.com South Africa
Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025 - GlobeNewswire
Craig-Hallum Sticks to Their Buy Rating for Actuate Therapeutics, Inc. (ACTU) - The Globe and Mail
Why Are Young Adults Getting More Pancreatic & Colon Cancer? - Targeted Oncology
Younger Adults See Sharp Rise in Pancreas & Colon Cancer, Study Shows - Targeted Oncology
Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - The Manila Times
Actuate Therapeutics to Present Topline Phase 2 Data of Elraglusib at 2025 ASCO Annual Meeting - Nasdaq
Actuate to Present Elraglusib Phase 2 Topline Data at the - GlobeNewswire
Actuate Therapeutics (NASDAQ:ACTU) Now Covered by Analysts at Craig Hallum - Defense World
Finanzdaten der Actuate Therapeutics Inc-Aktie (ACTU)
Es liegen keine Finanzdaten für Actuate Therapeutics Inc (ACTU) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Actuate Therapeutics Inc-Aktie (ACTU) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bios Equity COF, LP | Director |
Aug 14 '24 |
Buy |
8.00 |
500,000 |
4,000,000 |
1,259,427 |
| Bios Equity COF, LP | Director |
Aug 14 '24 |
Sale |
9.00 |
24,999 |
224,991 |
131,248 |
| Fletcher Aaron G.L. | Director |
Aug 14 '24 |
Buy |
8.00 |
500,000 |
4,000,000 |
1,259,427 |
| Fletcher Aaron G.L. | Director |
Aug 14 '24 |
Sale |
9.00 |
24,999 |
224,991 |
131,248 |
| Kreis Leslie W. | 10% Owner |
Aug 14 '24 |
Buy |
8.00 |
500,000 |
4,000,000 |
1,259,427 |
| Kreis Leslie W. | 10% Owner |
Aug 14 '24 |
Sale |
9.00 |
24,999 |
224,991 |
131,248 |
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):